VIR NASDAQ
Vir Biotechnology, Inc.
1W: +7.7%
1M: +10.1%
3M: +33.9%
YTD: +94.8%
1Y: +93.5%
3Y: +36.9%
5Y: -71.3%
$11.57
+0.53 (+4.80%)
Pre-Market: $11.59 (+0.02, +0.17%)
Weekly Expected Move ±7.6%
$9
$10
$11
$11
$12
Credit Risk of going bust: lower than 57% of companies Debt: 4.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.07 (down 99.4%), Vir Biotechnology, Inc. would be worth roughly what it owes.
Total debt $93.3M against a stock market value of $1.96B.
Distance to default 5.86 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $46.6M (short-term plus half of long-term), stock volatility 63.1%; Altman Z'' 2.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.07 (down 99.4%), Vir Biotechnology, Inc. would be worth roughly what it owes.
Total debt $93.3M against a stock market value of $1.96B.
Distance to default 5.86 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $46.6M (short-term plus half of long-term), stock volatility 63.1%; Altman Z'' 2.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
23 relationships23
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-05-24
Earliest Filing
2026-02-23
Latest Filing
partner: 21
supplier: 1
customer: 1
Counterparties (Filed by VIR)
23 relationshipsCompanies named in VIR's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Astellas US LLC | — | partner | Entered into a collaboration and license agreement to co-develop and co-commercialize VIR-5500 | 2026-02-23 | View |
| Astellas Pharma Inc. | — | partner | Indirect parent of Astellas US LLC and co-developer of VIR-5500 | 2026-02-23 | View |
| Sanofi S.A. | SNYNF | partner | Holds intellectual property rights for PRO-XTEN and receives a portion of collaboration proceeds | 2026-02-23 | View |
| Amunix Pharmaceuticals, Inc. | — | partner | Owner of the PRO-XTEN trademark, a Sanofi company | 2026-02-23 | View |
| Norgine Pharma UK Limited | — | partner | Exclusive license agreement for commercial rights to tobevibart and elebsiran combination for treating chronic hepatitis | 2025-12-16 | View |
| Amunix Pharmaceuticals, Inc. | — | partner | Licensor of masked T-cell engagers and protease-cleavable masking platform to Vir Biotechnology | 2024-09-10 | View |
| Sanofi | SNYNF | partner | Parent company of Amunix Pharmaceuticals, Inc. and co-licensor in the transaction with Vir Biotechnology | 2024-09-10 | View |
| Amunix Pharmaceuticals, Inc. | — | partner | License agreement for masked T-cell engagers and protease-cleavable masking platform | 2024-08-01 | View |
| Sanofi | SNYNF | partner | Parent company of Amunix Pharmaceuticals, Inc. | 2024-08-01 | View |
| Glaxo Wellcome UK Limited | — | partner | Termination of collaboration agreement on Influenza Program | 2024-02-22 | View |
| Cowen and Company, LLC | — | partner | Sales agent for the offering of common stock | 2023-11-03 | View |
| Glaxo Wellcome UK Limited | — | partner | Collaboration partner in the CoV Vaccine and CoV Antibody Programs | 2023-02-13 | View |
| Beecham S.A. | — | partner | Original collaboration partner whose rights were assigned to GSK Bio | 2023-02-13 | View |
| GlaxoSmithKline Biologicals S.A. | — | partner | Assignee of the DCA from Beecham and current collaboration partner | 2023-02-13 | View |
| WuXi Biologics (Hong Kong) Limited | — | partner | Counterparty whose termination of agreement triggered rights reversion | 2023-02-13 | View |
| Glaxo Wellcome UK Limited | — | partner | Collaboration partner in the Antibody Program and payor of upfront payment and royalties under DCA Amendment | 2022-06-03 | View |
| Beecham S.A. | — | partner | Original party to the Definitive Collaboration Agreement, rights assigned to GlaxoSmithKline Biologicals S.A. | 2022-06-03 | View |
| WuXi Biologics (Hong Kong) Limited | — | partner | Previous licensee of antibody rights in China/Hong Kong/Macau/Taiwan whose rights were terminated and reverted to Vir Bi | 2022-06-03 | View |
| GlaxoSmithKline Biologicals S.A. | — | partner | Assignee of rights from Beecham S.A. and sole developer/commercializer of VIR-7831 Antibody Product in China/Hong Kong/M | 2022-06-03 | View |
| WuXi Biologics (Hong Kong) Limited | — | partner | Termination of Development and Manufacturing Collaboration Agreement for VIR-7831 in Greater China | 2022-05-20 | View |
| KRE Exchange Owner LLC | — | supplier | Lease agreement for office and laboratory space | 2021-12-22 | View |
| Dropbox, Inc. | DBX | customer | Previous sublessee of the premises | 2021-12-22 | View |
| Glaxo Wellcome UK Limited | — | partner | Entered into a definitive collaboration agreement for influenza mAbs, functional genomics, and pathogen programs. | 2021-05-24 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-14 | Unregistered Equity Sales; Other Events; Exhibits | View | |
| 2026-10-08 | Other Events; Exhibits | View | |
| 2026-10-01 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-08-05 | Earnings Release; Exhibits | View | |
| 2026-07-24 | Officer/Director Change | View | |
| 2026-06-10 | Officer/Director Change | View | |
| 2026-05-28 | Officer/Director Change; Shareholder Vote | View | |
| 2026-05-06 | Earnings Release; Exhibits | View | |
| 2026-04-10 | Officer/Director Change | View | |
| 2026-03-04 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-03-02 | Other Events | View | |
| 2026-02-26 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2026-02-23 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Unregistere | Agreement | View |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-12-16 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-11-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-24 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-29 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-09 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR